Literature DB >> 1481351

Approaches to the identification of non-essential genes of African swine fever virus.

C Mettraux1, M Ackermann, J D Tratschin, U Kihm.   

Abstract

It is poorly understood why vaccines could not be developed for the control and prevention of African swine fever (ASF) virus infection. The aim of our study was to identify genes non-essential for ASF virus replication because there were indications that certain viral gene products, which apparently are non-essential for viral replication, conferred protection from death due to ASF. A cosmid library representing the genome of ASF virus strain France 64 was established and characterized. Then, in order to inactivate viral genes by insertion, the beta-galactosidase (beta-gal) gene was introduced either randomly or at specific locations of selected cloned DNA fragments. These constructions were transfected into cells which had been previously infected with a cell-culture-adapted viral strain in order to allow the generation of recombinant progeny virus. Viable recombinant progeny was identified by at least one of the following means: (1) expression of beta-gal; (2) detection of beta-gal specific DNA by plaque hybridization, and (3) absence of a functional product of the inactivated gene. Presently, we are characterizing a recombinant virus with an insertionally inactivated thymidine kinase gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481351     DOI: 10.1016/0378-1135(92)90039-v

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  2 in total

Review 1.  Immunoprophylaxis against important virus disease of horses, farm animals and birds.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

Review 2.  Veterinary vaccine development from an industrial perspective.

Authors:  J G M Heldens; J R Patel; N Chanter; G J Ten Thij; M Gravendijck; V E J C Schijns; A Langen; Th P M Schetters
Journal:  Vet J       Date:  2008-03-03       Impact factor: 2.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.